Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Regulatory Insight
Spotlight Article

Preclinical considerations for assessment of cellular & gene therapy products: FDA perspective

Meeting Preclinical Data Requirements For Cell & Gene Therapies

Gaya Hettiarachchi & Wei Liang

The conduct of a clinical trial for an investigational cellular or gene therapy (CGT) product is governed by the Code of Federal Regulations (CFR) Title 21, Part 312 to ensure the safety and rights of human subjects in all phases of a clinical investigation. Preclinical evaluation of CGT products in vitro and in vivo contributes significantly to characterization of the product benefit:risk profile throughout clinical development. Major objectives of the preclinical program for CGT products are to establish the scientific rationale to support the planned clinical investigation and to assess any toxicities associated with administration of the investigational CGT product. This article will discuss: 1) potential safety concerns associated with CGT products; 2) preclinical testing approaches to support an Investigational New Drug (IND) submission for a first-in-human (FIH) clinical trial and a Biologics License Application (BLA); and 3) early communications with the Food and Drug Administration (FDA).

DOI: 10.18609/cgti.2019.049
Citation: Cell & Gene Therapy Insights 2019; 5(7), 443-454.
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog